Home > Insider Trading > Filing (0001209191-22-006596)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601830	Recursion Pharmaceuticals Inc.	RXRX	Biological Products, (No Disgnostic Substances) (2836)	464099738

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1856369	Christopher Gibson	C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2022-01-31	19,858	$0.00	43,328	No	4	C	Direct
Class A Common Stock	Disposition	2022-01-31	19,858	$11.73	23,470	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Class B Common Stock	Disposition	2022-01-31	19,858	$0.00	19,858	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,758,484			No	4	C	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Class A Common Stock	Stock Option (Right to Buy)	$2.47	2030-12-30	1,471,354	1,471,354	Direct
Class A Common Stock	Class B Common Stock	$0.00		550,000	550,000	Indirect
Class A Common Stock	Class B Common Stock	$0.00		550,000	550,000	Indirect
Class A Common Stock	Class B Common Stock	$0.00		146,875	146,875	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2030-12-30	1,471,354	1,471,354	Direct
	550,000	550,000	Indirect
	550,000	550,000	Indirect
	146,875	146,875	Indirect

Footnotes

Represents the conversion of Class B Common Stock into Class A Common Stock.
Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral.
This transaction was executed in multiple trades at prices ranging from $11.43 to $11.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.